Steroid-resistant/JJ
asthma/NN
./.
=====
Cellular/JJ
mechanisms/NNS
contributing/VBG
to/TO
inadequate/JJ
response/NN
to/TO
glucocorticoid/NN
therapy/NN
./.

The/DT
current/JJ
study/NN
examined/VBD
whether/IN
alterations/NNS
in/IN
glucocorticoid/NN
receptor/NN
(/(
GR/NN
)/)
binding/NN
contribute/VBP
to/TO
poor/JJ
response/NN
to/TO
glucocorticoid/NN
therapy/NN
in/IN
asthma/NN
./.
=====
29/CD
asthma/NN
patients/NNS
with/IN
forced/VBN
expiratory/JJ
volume/NN
in/IN
1/CD
s/NN
(/(
FEV1/NN
)/)
</JJR
70/CD
%/NN
predicted/VBN
were/VBD
studied/VBN
./.
=====
Patients/NNS
were/VBD
classified/VBN
as/IN
steroid/NN
sensitive/JJ
(/(
SS/JJ
)/)
if/IN
their/PRP$
morning/NN
FEV1/NN
increased/VBD
>/RBR
30/CD
%/NN
after/IN
a/DT
1-wk/JJ
course/NN
of/IN
oral/JJ
prednisone/NN
20/CD
mg/NN
twice/RB
daily/RB
and/CC
steroid/NN
resistant/JJ
(/(
SR/JJ
)/)
if/IN
they/PRP
failed/VBD
to/TO
increase/VB
>/RBR
15/CD
%/NN
./.
=====
PBMC/NN
obtained/VBN
from/IN
these/DT
two/CD
groups/NNS
,/,
17/CD
SR/JJ
and/CC
12/CD
SS/JJ
,/,
as/RB
well/RB
as/IN
12/CD
normal/JJ
controls/NNS
were/VBD
analyzed/VBN
./.
SR/JJ
patients/NNS
had/VBD
two/CD
distinguishable/JJ
GR/NN
binding/NN
abnormalities/NNS
:/:
15/CD
of/IN
the/DT
17/CD
SR/JJ
patients/NNS
demonstrated/VBD
a/DT
significantly/RB
reduced/VBN
GR/NN
binding/NN
affinity/NN
,/,
as/IN
compared/VBN
with/IN
SS/JJ
patients/NNS
(/(
P/NN
=/JJ
0.0001/CD
)/)
and/CC
normal/JJ
controls/NNS
(/(
P/NN
=/JJ
0.0001/CD
)/)
./.
=====
This/DT
defect/NN
was/VBD
localized/JJ
to/TO
T/NN
cells/NNS
and/CC
reverted/VBD
to/TO
normal/JJ
after/IN
48/CD
h/NN
in/IN
culture/NN
media/NNS
./.
=====
However/RB
,/,
incubation/NN
with/IN
a/DT
combination/NN
of/IN
IL-2/NN
and/CC
IL-4/NN
sustained/VBD
this/DT
abnormality/NN
./.
=====
The/DT
other/JJ
two/CD
SR/JJ
patients/NNS
had/VBD
an/DT
abnormally/RB
low/JJ
GR/NN
number/NN
with/IN
normal/JJ
binding/NN
affinity/NN
that/WDT
was/VBD
not/RB
limited/VBN
to/TO
T/NN
cells/NNS
./.
=====
Furthermore/RB
,/,
GR/NN
number/NN
failed/VBD
to/TO
normalize/VB
after/IN
incubation/NN
in/IN
media/NNS
alone/RB
or/CC
IL-2/NN
and/CC
IL-4/NN
./.
=====
Therefore/RB
,/,
SR/JJ
asthma/NN
may/MD
be/VB
due/JJ
to/TO
more/JJR
than/IN
one/CD
abnormality/NN
,/,
the/DT
majority/NN
related/JJ
to/TO
a/DT
reversible/JJ
cytokine-induced/JJ
reduction/NN
in/IN
GR/NN
binding/NN
affinity/NN
and/CC
the/DT
second/JJ
related/JJ
to/TO
an/DT
irreversible/JJ
reduction/NN
in/IN
GR/NN
number/NN
./.
=====
These/DT
findings/NNS
may/MD
have/VB
important/JJ
implications/NNS
for/IN
the/DT
design/NN
of/IN
alternative/JJ
treatment/NN
approaches/NNS
for/IN
recalcitrant/JJ
asthma/NN
./.